Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Exelixis Inc.
Headquarters: South San Francisco, CA, United States of America
Website: http://www.exelixis.com
Year Founded: 1994
Status: Public
Industry Sector: HealthTechnology
CEO: Michael M. Morrissey, PhD
Number Of Employees: 1,147
Enterprise Value: $9,116,780,920
PE Ratio: 20.69
Exchange/Ticker 1: NASDAQ:EXEL
Exchange/Ticker 2: N/A
Latest Market Cap: $10,266,035,200
BioCentury | Mar 4, 2025
Management Tracks
Head of R&D Robert Lenz to leave Neumora
Plus: Jeffrey Sevigny named CMO of Rapport, and updates from Garuda, Metis, Ovid and more
BioCentury | Jan 17, 2025
Finance
4Q24 Wrap: They all fall down
Winners, losers in biotech stock tiers in 4Q24
BioCentury | Oct 15, 2024
Management Tracks
Rubin leaving Boundless as CFO, new CSOs for C4, Avacta and Commit
Plus: David Cameron named chair of Oxford-Harrington Rare Disease Centre’s advisory council, and updates from Twist, Boundless, Lucy and more
BioCentury | Aug 13, 2024
Product Development
Vir evolves from antiviral one-stop shop to protein engineering play
Shedding non-protein platforms and bringing in masked bispecifics for cancer, the company’s pivot highlights the challenges of its founding thesis.
BioCentury | Mar 6, 2024
Management Tracks
EyePoint names Ribeiro CMO
Plus: Ford joins Prothena and updates from Atlas, Osmol and CytoVale
BioCentury | Jan 6, 2024
Management Tracks
Management moves abound on eve of JPM, including new chairs for Sobi, Corteria
Plus: Zaderej to retire as AxoGen CEO and updates from AxoGen, Delfi, Illumina, Evozyne, Kiyatec, Sosei, Twist, Novocure, Be Bio, Novo Holdings, Bioluminescence and more
BioCentury | Jan 4, 2024
Management Tracks
Lanthaler leaving Evotec as CEO
Plus: Morphic’s CEO Tipirneni returns and more from Kojin, Harvard, Star, Novavax, Entrada, Brii, Switch, SmartCella
BioCentury | Nov 15, 2023
Deals
Alkermes oncology spinout Mural charts its future
Newly independent cancer biotech looks to twin 2025 readouts of IL-2 program that leads pipeline of engineered cytokine therapeutics
BioCentury | Sep 27, 2023
Deals
Insilico’s evolving AI deals: from ‘death by pilot’ to $80M up front
The AI company’s Exelixis partnership highlights its strategic pivots in a shifting landscape
Items per page:
1 - 10 of 749